Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Evaluation of the Monoclonal Antibody, RAV12, in Combination With Standard Gemcitabine in the Treatment of Patients With Metastatic Pancreatic Cancer Who Have Not Been Previously Treated for Metastatic Disease

Trial Profile

A Phase 2 Evaluation of the Monoclonal Antibody, RAV12, in Combination With Standard Gemcitabine in the Treatment of Patients With Metastatic Pancreatic Cancer Who Have Not Been Previously Treated for Metastatic Disease

Discontinued
Phase of Trial: Phase II

Latest Information Update: 18 Dec 2012

At a glance

  • Drugs RAV 12 (Primary) ; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 18 Apr 2012 Actual end date (Mar 2009) added as reported by ClinicalTrials.gov.
    • 18 Apr 2012 Company (MacroGenics) added and actual patient number is 2 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top